The total Chinese pharmaceutical market reached RMB 828.4 billion (US$ 120.8 billion, at an exchange rate of US $1 = RMB 6.83) with an annual growth rate of 26.50% in 2008. The growth rate, as well as the absolute size of the rapidly-expanding Chinese pharmaceutical market, is remarkable and the categorization of the Chinese pharmaceutical market as one of the “emerging pharmaceutical market” will need to be reconsidered.
Many pharmaceutical companies have realized this and are focusing on the Chinese market to support future growth. To capitalize on this market, pharma companies need reliable hospital drug utilization data from China.
Medtech Insight & Draco Healthcare Present
The Chinese Hospital Drug Utilization Volume
2nd Edition 2009 – October 2009
Even though the current Chinese pharmaceutical market is still mainly a generic market, many innovative drugs have been rapidly up-taken by large Chinese hospitals in major cities. Some of highly-priced oncology drugs such as erlotinib and trastuzumab, have made the list of top 20 cancer drugs (by sales) in the last few years.
Annual drug sales in each of cancer, blood diseases, liver diseases, dermatoses, hypertension, diabetes, dementia, and hyperlipidemics passed US $1 billion in 2008. Sales of cancer drugs in the Chinese hospital market reached US $4.6 billion, followed by blood products with sales of U.S $4.0 billion. Drug sales in most therapeutic areas enjoyed double digit growth rates in 2008 with the exception of skin disease, eye disease, allergy and BPH, drug sales.
This Second Edition of (Report DHP-8009) the China Pharma Executive Summary provides hospital drug utilization data for a number of key therapeutic areas, including asthma, cancer, liver diseases, diabetes, hypertension, depression, allergy, dementia, benign prostate hyperplasia (BPH), ophthalmology, hyperlipoidemia, rheumatoid arthritis, dermatosis, and blood products.
Key contents include:
· 2008 annual drug sales in the Chinese hospital market for each therapeutic area. Drug prices are based on the hospital drug purchase prices in 2008 for all drug utilization data in this report.
· Sales and market shares of top 20 manufacturers in each therapeutic area.
· Sales and market shares of top drugs in each therapeutic area.
Table of Contents Overview:
Section 1: China Benign Prostate Hyperplasia (BPH) Drug Market
1.1 Competition landscape of the Chinese BPH hospital drug market
1.2 Manufacturers and their market shares in the Chinese BPH drug market
Section 2: China Asthma Drug Market
2.1 Competition landscape of the Chinese asthma drug market
2.2 Manufacturers and their market shares in the Chinese asthma drug market
Section 3: China Depression Drug Market
3.1 Competition landscape of the Chinese depression drug market
3.2 Manufacturers and their market shares in the Chinese depression drug market
Section 4: China Dementia Drug Market
4.1 Competition landscape of the Chinese dementia drug market
4.2 Manufacturers and their market shares of the Chinese dementia drug market
Section 5: China Cancer Drug Market
5.1 Competition landscape of the Chinese cancer drug market
5.2 Manufacturers and their market shares in the Chinese cancer drug market
Section 6: The China Allergy Drug Market
6.1 Competition landscape of the Chinese allergy drug market
6.2 Manufacturers and their market shares in the Chinese allergy drug market
Section 7: China Hypertension Drug Market
7.1 Competition landscape of the Chinese hypertension drug market
7.2 Manufacturers and their market shares in the Chinese hypertension drug market
Section 8: Dermatosis Drug Market
8.1 Competition landscape of the Chinese dermatosis drug market
8.2 Manufacturers and their market shares in the Chinese dermatosis drug market
Section 9: China Ophthalmological Drug Market
9.1 Competition landscape in the Chinese ophthalmological drug market
9.2 Manufacturers and their market shares in the Chinese ophthalmological drug market
Section 10: China Rheumatoid Arthritis (RA) Drug Market
10.1 Competition landscape of the Chinese RA drug market
10.2 Manufacturers and their market shares in the Chinese RA drug market
Section 11: China Diabetes Drug Market
11.1 Competition landscape of the Chinese diabetes drug market
11.2 Manufacturers and their market shares in the Chinese diabetes drug market in 2008
Section 12: Liver Disease Drug Market
12.1. Competition landscape of the Chinese liver disease drug market
12.2 Manufacturers, their market shares and sales in the Chinese liver disease drug market in 2008
Section 13: China Blood Product Market
13.1 Competition landscape of the Chinese blood product market
13.2 Manufacturers and their market shares in the Chinese blood product market
Section 14: China Hypolipidemics Drug Market
14.1 Competition landscape of the Chinese hypolipidemics drug market
14.2 Manufacturers and their market shares in the Chinese hypolipidemics drug market
